secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-05-27T23:59:59+00:00
Accession:  0000950170-22-010869
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics stockholders approve doubling authorized common stock to 300M shares
--------------------------------------------------------------------------------

- Shareholders approved amendment to increase authorized common shares from 150M to 300M (93,032,987 for, 758,293 against).
- Directors elected: Alexis Borisy, Mark Murcko, Laura Shawver (class II, three-year term).
- Non-binding advisory vote on executive compensation passed (83,645,401 for, 3,551,366 against).
- Ratification of Ernst & Young as independent auditor for FY2022 approved (93,772,475 for, 15,739 against).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/0000950170-22-010869-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022010869/rlay-20220527.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-010869

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer